Prosecution Insights
Last updated: May 29, 2026

Examiner: BUCHANAN, BAILEY CHEYENNE

Tech Center 1600 • Art Units: 1682

This examiner grants 50% of resolved cases

Performance Statistics

50.0%
Allow Rate
-10.0% vs TC avg
76
Total Applications
+46.7%
Interview Lift
1362
Avg Prosecution Days
Based on 14 resolved cases, 2023–2026

Rejection Statute Breakdown

1.4%
§101 Eligibility
7.5%
§102 Novelty
74.2%
§103 Obviousness
2.0%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17921710 DETECTING PANCREATIC NEUROENDOCRINE TUMORS Final Rejection Mayo Foundation for Medical Education and Research
17668915 MATERIALS AND METHODS FOR DETERMINING CANCER RISK Final Rejection Mayo Foundation for Medical Education and Research
17640740 DETECTION OF CHLAMYDIA TRACHOMATIS NUCLEIC ACID VARIANTS Non-Final OA Gen-Probe Incorporated
18246456 METHOD FOR PREDICTING IMMUNOTHERAPY RESISTANCE Non-Final OA KONINKLIJKE PHILIPS N.V.
18298922 TRANSMEMBRANE NANOSENSOR ARRAYS FOR RAPID, ULTRA-SENSITIVE AND SPECIFIC DIGITAL QUANTIFICATION OF INTERNAL MICRO-RNA CONTENT OF INTACT EXOSOMES Non-Final OA ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
17793382 COMPOSITIONS AND METHODS FOR DETECTION OF OVARIAN CANCER Final Rejection Mercy BioAnalytics, Inc.
18323143 Double-Stranded DNA Deaminases and Uses Thereof Non-Final OA New England Biolabs, Inc.
17780926 UPPER URINARY TRACT UROTHELIAL CARCINOMA IDENTIFICATION METHOD Final Rejection KEIO UNIVERSITY
18006888 BIOMARKERS FOR DIAGNOSING AND MONITORING LUNG CANCER Non-Final OA SORBONNE UNIVERSITE
18075729 METHODS, COMPOSITIONS, AND KITS FOR DETECTING ALLELIC VARIANTS Non-Final OA LIFE TECHNOLOGIES CORPORATION
17760652 HUMAN MITOCHONDRIAL DNA SEQUENCING BY TARGETED AMPLIFICATION OF MULTIPLEX PROBES (MTDNA-STAMP) Final Rejection CORNELL UNIVERSITY
17384241 DETECTING CANCER, CANCER TISSUE OF ORIGIN, AND/OR A CANCER CELL TYPE Final Rejection GRAIL, LLC
17890694 METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING SUBJECTS AT RISK OF POOR CANCER SURVIVAL Non-Final OA MEMORIAL SLOAN-KETTERING CANCER CENTER
17632783 CANCER DETECTION AND CLASSIFICATION Final Rejection The United States of America, as represented by the Secretary, Department of Health and Human Servic
18450653 KIT FOR IDENTIFYING TUMOR TISSUE-OF-ORIGIN AND DATA ANALYSIS METHOD Non-Final OA Hangzhou ShengTing Medical Technology Ltd.
18253582 METHOD FOR ISOLATING NUCLEIC ACID USING BINDING BUFFER INCLUDING COMPOUND HAVING LOW OR INTERMEDIATE DIELECTRIC CONSTANT Non-Final OA BIONEER CORPORATION
18255113 METHOD FOR PREIMPLANTATION GENETIC SCREENING OF EMBRYOS Non-Final OA REPROBIOGEN INC.
18254179 Ribosomal profiling in single cells Non-Final OA Koninklijke Nederlandse Akademie van Wetenschappen
17716395 CELL-FREE DNA METHYLATION AND NUCLEASE-MEDIATED FRAGMENTATION Final Rejection GRAIL, Inc.
17980271 Purified Enriched Population Exosomes Derived From Individuals With A Chronic Progressive Lung Disease For Noninvasive Detection, Staging, And Medical Monitoring Of Disease Progression Non-Final OA Exopharma, Inc
17770807 SAMPLE PREPARATION AND SEQUENCING ANALYSIS FOR REPEAT EXPANSION DISORDERS AND SHORT READ DEFICIENT TARGETS Final Rejection JumpCode Genomics, Inc.
17757847 METHOD OF DETECTING EPIGENETIC MODIFICATION Final Rejection Biofidelity Ltd
17787114 COMPOSITIONS AND METHODS FOR TREATING OR AMELIORATING A MYCOBACTERIUM TUBERCULOSIS INFECTION Non-Final OA San Diego State University (SDSU )Foundation, dba San Diego State University Research Foundation
17309902 METHYLATION MODIFICATION-BASED TUMOR MARKER STAMP-EP6 Non-Final OA SHANGHAI EPIPROBE BIOTECHNOLOGY CO., LTD.
17714271 METHOD FOR DETERMINING WHETHER BIOLOGICAL SAMPLE HASORIGINATED FROM LIVER CANCER TISSUE Non-Final OA LEPIDYNE CO., LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month